A5009956554- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Brain Metastases and Treatment
- Metastasis and carcinoma case studies
- Multiple and Secondary Primary Cancers
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Cancer Diagnosis and Treatment
- Genomics and Chromatin Dynamics
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Circular RNAs in diseases
- Lung Cancer Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Drug-Induced Ocular Toxicity
- Epigenetics and DNA Methylation
- Renal cell carcinoma treatment
- RNA Research and Splicing
- MicroRNA in disease regulation
- Occupational and environmental lung diseases
- Abdominal Trauma and Injuries
Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2025
Xingtai People's Hospital
2024
Hebei Medical University
2024
Tongji University
2024
University of South China
2024
Shanghai Pulmonary Hospital
2024
National Clinical Research
2022
Peking Union Medical College Hospital
2022
Objective This real-world study aimed to investigate the efficacy and safety of palbociclib plus endocrine therapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer real world a Chinese population. Methods The clinical data consecutively enrolled from Cancer Hospital Academy Medical Sciences, Shenzhen Center, University Hong Kong - were collected. Progression-free survival curves generated using log-rank tests Kaplan-Meier...
A substantial need for effective and safe treatment options is still unmet patients with heavily pre-treated human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Herein, we assessed the efficacy safety of pyrotinib plus trastuzumab chemotherapy in treated HER2-positive MBC.
Purpose Splenic metastases (SM) from breast cancer (SMBC) are exceedingly rare. To date, the relevant literature is primarily based on pan-tumour species, with only a few studies exploring SM specifically in relation to cancer. As such, present retrospective study explored clinicopathological characteristics and prognoses of patients SMBC at care centre authors’ hospital. Methods Data newly diagnosed metastatic (MBC) between June 2017 2022 were extracted medical records Clinicopathological...
Anlotinib is a novel oral small-molecule tyrosine kinase inhibitor (TKI), which can inhibit angiogenesis. The purpose of this study was to evaluate the efficacy and safety anlotinib combined with chemotherapy in patients metastatic triple-negative breast cancer (TNBC). This phase II clinical trial included 40 TNBC who had previously received anthracycline and/or taxane treatment. All chemotherapy. primary endpoint progression-free survival (PFS). secondary endpoints overall (OS), objective...
Abstract Background Apatinib is an oral small‐molecule tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptor‐2. Oral vinorelbine a semisynthetic chemotherapeutic agent of alkaloids. and have been proved to be effective in the treatment metastatic breast cancer (mBC). At present, several small sample clinical trials explored efficacy apatinib combined with mBC. Methods This retrospective study included 100 human epidermal receptor‐2 (HER2)‐negative mBC patients who...
Background More than half of the metastatic breast cancer patients with brain metastases (BCBM) are HER-2 negative, and prognosis HER2-negative BCBM is dismal. But few clinical trials have investigated systemic therapies for this subgroup patients.Methods This real-world study included 58 BCBMs who received low-dose apatinib (250 mg daily) in combination chemotherapy between 18 March 2017 31 December 2021. The objective response rate (ORR) central nervous system, benefit (CBR),...
For patients with hormone receptor-positive (HR
Background: Vinorelbine can be used to treat metastatic breast cancer as a single agent or in combination with other chemotherapy agents, although there is little real-world data for its use, particularly the oral form, China. The current study aimed explore efficacy and safety of vinorelbine patients clinical practice. Methods: A total 194 received treatment between February 2017 January 2021 at National Cancer Center/National Clinical Research Center Cancer/Cancer Hospital & Shenzhen...
The most common sites of metastasis for breast cancer are the soft tissues, bones, lungs, liver and brain; however, metastases to gastrointestinal tract thyroid gland from rarely occur. present study describes case a 30-year-old woman who developed gastric 5 years after her initial diagnosis invasive ductal carcinoma. pathological when receiving modified radical mastectomy was carcinoma, further immunohistochemical examination revealed be estrogen receptor (-), progesterone human epidermal...
Background: The epidermal growth factor receptor 2 (<i>HER2</i>) is overexpressed in 30% of breast cancers, and this overexpression strongly correlated with a poor prognosis. Herceptin common treatment for HER2-positive cancer; however, cancer cells tend to adapt gradually the drug, rendering it ineffective. study revealed an association between methylation status Homeobox C8 (<i>HOXC8</i>) gene tumor development. Therefore, paramount importance delve into interaction <i>HOXC8</i> cancer,...
The efficacy and tolerability of eribulin mesylate, a synthetic halichondrin B analog, in patients with metastatic breast cancer (MBC) previously treated anthracyclines taxanes have been established. Acute-on-chronic liver failure (ACLF) is clinical syndrome manifesting as acute severe hepatic derangement resulting from varied insults established chronic disease or cirrhosis who did not receive eribulin. A middle-aged woman diagnosed MBC diffuse metastases was pretreated multi-line...